<DOC>
	<DOCNO>NCT00002270</DOCNO>
	<brief_summary>To study effectiveness alpha interferon ( IFN-A2b ) zidovudine ( AZT ) treat progressive multifocal leukoencephalopathy ( PML ) complication HIV-1 infection .</brief_summary>
	<brief_title>A Pilot Study Efficacy Recombinant Alpha Interferon ( IFN-A2b ) Zidovudine ( AZT ) Treatment Progressive Multifocal Leukoencephalopathy ( PML ) Complicating HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Leukoencephalopathies</mesh_term>
	<mesh_term>Leukoencephalopathy , Progressive Multifocal</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV seropositivity ELISA Western blot . Biopsy proven progressive multifocal leukoencephalopathy ( PML ) . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Intolerant interferon . Prior concomitant central nervous system disease ( CNS ) toxoplasmosis , multiple sclerosis ( MS ) , neurosyphilis . Patients follow exclude : Intolerant interferon . Prior concomitant central nervous system disease ( CNS ) toxoplasmosis , multiple sclerosis ( MS ) , neurosyphilis . Prior Medication : Excluded : Patients receive interferon reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 1991</verification_date>
	<keyword>Leukoencephalopathy , Progressive Multifocal</keyword>
	<keyword>Interferon Alfa-2b</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>